| [1] |
FIORE M, MARAOLO AE, GENTILE I, et al. Current concepts and future strategies in the antimicrobial therapy of emerging Gram-positive spontaneous bacterial peritonitis[J]. World J Hepatol, 2017, 9(30): 1166-1175. DOI: 10.4254/wjh.v9.i30.1166 |
| [2] |
SHIZUMA T. Spontaneous bacterial and fungal peritonitis in patients with liver cirrhosis: A literature review[J]. World J Hepatol, 2018, 10(2): 254-266. DOI: 10.4254/wjh.v10.i2.254 |
| [3] |
FLOCH MH. Intestinal microecology in health and wellness[J]. J Clin Gastroenterol, 2011, 10: s108-s110.
|
| [4] |
|
| [5] |
D'ARGENIO V, SALVATORE F. The role of the gut microbiome in the healthy adult status[J]. Clin Chim Acta, 2015, 451(Pt A): 97-102.
|
| [6] |
SMITH K. Liver disease: Kupffer cells regulate the progression of ALD and NAFLD[J]. Nat Rev Gastroenterol Hepatol, 2013, 10(9): 503.
|
| [7] |
PETRASEK J, BALA S, CSAK T, et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice[J]. J Clin Invest, 2012, 122(10): 3476-3489. DOI: 10.1172/JCI60777 |
| [8] |
|
| [9] |
|
| [10] |
MILOSEVIC I, VUJOVIC A, BARAC A, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: A review of the literature[J]. Int J Mol Sci, 2019, 20(2): 395. DOI: 10.3390/ijms20020395 |
| [11] |
REUTER B, BAJAJ JS. Microbiome: Emerging concepts in patients with chronic liver disease[J]. Clin Liver Dis, 2020, 24(3): 493-520. DOI: 10.1016/j.cld.2020.04.006 |
| [12] |
SCHULTALBERS M, TERGAST TL, SIMON N, et al. Frequency, characteristics and impact of multiple consecutive nosocomial infections in patients with decompensated liver cirrhosis and ascites[J]. United European Gastroenterol J, 2020, 8(5): 567-576. DOI: 10.1177/2050640620913732 |
| [13] |
OLSON JC, WENDON JA, KRAMER DJ, et al. Intensive care of the patient with cirrhosis[J]. Hepatology, 2011, 54(5): 1864-1872. DOI: 10.1002/hep.24622 |
| [14] |
SEKI E, SCHNABL B. Role of innate immunity and the microbiota in liver fibrosis: Crosstalk between the liver and gut[J]. J Physiol, 2012, 590(3): 447-458. DOI: 10.1113/jphysiol.2011.219691 |
| [15] |
de ROZA MA, KAI L, KAM JW, et al. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis[J]. World J Gastroenterol, 2019, 25: 4933-4944. DOI: 10.3748/wjg.v25.i33.4933 |
| [16] |
QIN N, YANG F, LI A, et al. Alterations of the human gut microbiome in liver cirrhosis[J]. Nature, 2014, 513(7516): 59-64. DOI: 10.1038/nature13568 |
| [17] |
BAJAJ JS, BETRAPALLY NS, GILLEVET PM. Decompensated cirrhosis and microbiome interpretation[J]. Nature, 2015, 525(7569): e1-e2. DOI: 10.1038/nature14851 |
| [18] |
WANG Y, PAN CQ, XING H. Advances in gut microbiota of viral hepatitis cirrhosis[J]. Biomed Res Int, 2019, 2019: 9726786.
|
| [19] |
USAMI M, MIYOSHI M, YAMASHITA H. Gut microbiota and host metabolism in liver cirrhosis[J]. World J Gastroenterol, 2015, 21(41): 11597-11608. DOI: 10.3748/wjg.v21.i41.11597 |
| [20] |
BAJAJ JS, BETRAPALLY NS, HYLEMON PB, et al. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy[J]. Hepatology, 2015, 62(4): 1260-1271. DOI: 10.1002/hep.27819 |
| [21] |
LUAN YT, CAI WJ, JIANG SL, et al. A comparative study of intestinal flora between hepatitis B cirrhosis patients with or without ascites[J]. J Clin Hepatol, 2020, 36(7): 1520-1526. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.07.015 |
| [22] |
WIEST R, KRAG A, GERBES A. Spontaneous bacterial peritonitis: Recent guidelines and beyond[J]. Gut, 2012, 61(2): 297-310. DOI: 10.1136/gutjnl-2011-300779 |
| [23] |
HADJIVASILIS A, TZANIS A, IOAKIM KJ, et al. The diagnostic accuracy of ascitic calprotectin for the early diagnosis of spontaneous bacterial peritonitis: Systematic review and meta-analysis[J]. Eur J Gastroenterol Hepatol, 2021, 33(3): 312-318.
|
| [24] |
GUNDLING F, SCHMIDTLER F, HAPFELMEIER A, et al. Fecal calprotectin is a useful screening parameter for hepatic encephalopathy and spontaneous bacterial peritonitis in cirrhosis[J]. Liver Int, 2011, 31(9): 1406-1415. DOI: 10.1111/j.1478-3231.2011.02577.x |
| [25] |
WEIL D, HEURGUE-BERLOT A, MONNET E, et al. Accuracy of calprotectin using the Quantum Blue Reader for the diagnosis of spontaneous bacterial peritonitis in liver cirrhosis[J]. Hepatol Res, 2019, 49(1): 72-81. DOI: 10.1111/hepr.13239 |
| [26] |
JUNG Y, WEN T, MINGLER MK, et al. IL-1β in eosinophil-mediated small intestinal homeostasis and IgA production[J]. Mucosal Immunol, 2015, 8(4): 930-942. DOI: 10.1038/mi.2014.123 |
| [27] |
LV XY, DING HG, ZHENG JF, et al. Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study[J]. World J Gastroenterol, 2020, 26(2): 199-218. DOI: 10.3748/wjg.v26.i2.199 |
| [28] |
ASSIMAKOPOULOS SF, TSAMANDAS AC, TSIAOUSSIS GI, et al. Altered intestinal tight junctions' expression in patients with liver cirrhosis: A pathogenetic mechanism of intestinal hyperpermeability[J]. Eur J Clin Invest, 2012, 42(4): 439-446. DOI: 10.1111/j.1365-2362.2011.02609.x |
| [29] |
RAWAT M, NIGHOT M, AL-SADI R, et al. IL1B increases intestinal tight junction permeability by upregulation of MIR200C-3p, which degrades occludin mRNA[J]. Gastroenterology, 2020, 159(4): 1375-1389. DOI: 10.1053/j.gastro.2020.06.038 |
| [30] |
SCARPELLINI E, VALENZA V, GABRIELLI M, et al. Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: Is the ring closed?[J]. Am J Gastroenterol, 2010, 105(2): 323-327. DOI: 10.1038/ajg.2009.558 |
| [31] |
MUÑOZ L, JOSÉ BORRERO M, UBEDA M, et al. Interaction between intestinal dendritic cells and bacteria translocated from the gut in rats with cirrhosis[J]. Hepatology, 2012, 56(5): 1861-1869. DOI: 10.1002/hep.25854 |
| [32] |
APPENRODT B, GRVNHAGE F, GENTEMANN MG, et al. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis[J]. Hepatology, 2010, 51(4): 1327-1333. DOI: 10.1002/hep.23440 |
| [33] |
NISCHALKE HD, BERGER C, ALDENHOFF K, et al. Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis[J]. J Hepatol, 2011, 55(5): 1010-1016. DOI: 10.1016/j.jhep.2011.02.022 |
| [34] |
BRUNS T, PETER J, REUKEN PA, et al. NOD2 gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis[J]. Liver Int, 2012, 32(2): 223-230. DOI: 10.1111/j.1478-3231.2011.02561.x |
| [35] |
HOLLMAN DA, MILONA A, van ERPECUM KJ, et al. Anti-inflammatory and metabolic actions of FXR: Insights into molecular mechanisms[J]. Biochim Biophys Acta, 2012, 1821(11): 1443-1452. DOI: 10.1016/j.bbalip.2012.07.004 |
| [36] |
LUTZ P, BERGER C, LANGHANS B, et al. A farnesoid X receptor polymorphism predisposes to spontaneous bacterial peritonitis[J]. Dig Liver Dis, 2014, 46(11): 1047-1050. DOI: 10.1016/j.dld.2014.07.008 |
| [37] |
STEIB CJ, SCHEWE J, GERBES AL. Infection as a trigger for portal hypertension[J]. Dig Dis, 2015, 33(4): 570-576. DOI: 10.1159/000375352 |
| [38] |
QUAN M, XING HC. Research progress on intestinal flora and chronic liver diseases[J/CD]. Chin J Liver Dis (Electronic Version), 2019, 11(3): 26-30. (in Chinese)
全敏, 邢卉春. 肠道菌群与慢性肝病相关研究进展[J/CD]. 中国肝脏病杂志(电子版), 2019, 11(3): 26-30.
|
| [39] |
HORVATH A, DURDEVIC M, LEBER B, et al. Changes in the intestinal microbiome during a multispecies probiotic intervention in compensated cirrhosis[J]. Nutrients, 2020, 12(6): e1874. DOI: 10.3390/nu12061874 |
| [40] |
HORVATH A, LEBER B, SCHMERBOECK B, et al. Randomised clinical trial: The effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis[J]. Aliment Pharmacol Ther, 2016, 44(9): 926-935. DOI: 10.1111/apt.13788 |
| [41] |
DENG X, ZHENG C, WANG S, et al. Treatment with a probiotic combination reduces abdominal adhesion in rats by decreasing intestinal inflammation and restoring microbial composition[J]. Oncol Rep, 2020, 43(3): 986-998.
|
| [42] |
HⅡPPALA K, JOUHTEN H, RONKAINEN A, et al. The potential of gut commensals in reinforcing intestinal barrier function and alleviating inflammation[J]. Nutrients, 2018, 10(8): 988. DOI: 10.3390/nu10080988 |
| [43] |
MITTAL H, WYAWAHARE M, SISTLA S. Microbiological profile of pathogens in spontaneous bacterial peritonitis secondary to liver cirrhosis: A retrospective study[J]. Trop Doct, 2020, 50(2): 138-141. DOI: 10.1177/0049475520905745 |
DownLoad: